Spacer
Spacer
Referrals Clinical Trials Department Newsletter Additional Links
Spacer
Spacer
 Home
 Patient Care
 Neurosurgery Research
 Academics/Residency
 Faculty/Staff
 General Information
 Administrative Resources
Clinical Trials: Pediatric Program for the Treatment of Malignant Brain Tumors
Spacer
Home > Clinical Trials > Pediatric Program for the Treatment of Malignant Brain Tumors
Spacer

Questions about patients' participation in the following clinical trials can be directed to Cynthia Asiyo by calling 415.476.3982 or by e-mail at AsiyoC@peds.ucsf.edu. Alternatively, to contact the nurse practitioner in charge, please call 415.476.3831.
 
More information on Pediatric Brain Tumor Consortium (PTBC) studies, please visit their website.
 
Newly Diagnosed Tumor
 
Diffuse Pontine Glioma
Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas (PBTC 021)
This is a phase I trial for children with newly diagnosed, diffuse intrinsic brain stem gliomas and high-grade gliomas. For furhter details: http://www.pbtc.org/public/PBTC021%20Protocol%20Abstract.pdf
A Phase II Study of Motexafin-Gadolinium (NSC 695238, IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood
Children's Oncology Group Study ACNS0222. This phase II trial is studying how well giving motexafin gadolinium together with radiation therapy works in treating young patients with pontine glioma. For further details: http://www.clinicaltrials.gov/ct2/show/NCT00387790?term=ACNS0222&rank=1

High-Grade Glioma
Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas (PBTC 021)
This is a phase I trial for children with newly diagnosed, diffuse intrinsic brain stem gliomas and high-grade gliomas. For furhter details: http://www.pbtc.org/public/PBTC021%20Protocol%20Abstract.pdf

Low-Grade Glioma
A Phase II Study of Conformal Radiotherapy in Patients with Low-Grade Gliomas; a Groupwide Phase II Study
Children's Oncology Group Study ACNS0221

Medulloblastoma and Primitive Neural Ectodermal Tumor
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
Children's Oncology Group Study ACNS0331. This randomized phase III trial is studying standard-dose radiation therapy to see how well it works compared to reduced-dose craniospinal radiation therapy AND posterior fossa boost radiation therapy to see how well it works compared to tumor bed boost radiation therapy when given together with chemotherapy in treating young patients who have undergone surgery for newly diagnosed standard-risk medulloblastoma. For further details: http://www.clinicaltrials.gov/ct/show/NCT00085735?order=1
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Children's Oncology Group Study ACNS0332. This randomized phase III trial is studying different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma or supratentorial primitive neuroectodermal tumor. For further details: http://www.clinicaltrials.gov/ct/show/NCT00392327?order=1
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate
Children's Oncology Group Study ACNS0334
Germ Cell Tumor
Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
Children's Oncology Group Study ACNS0122. This phase II trial is studying how well neoadjuvant chemotherapy with or without surgery followed by radiation therapy with or without peripheral stem cell transplantation work in treating patients with intracranial germ cell tumors. For further details: http://www.clinicaltrials.gov/ct2/show/NCT00047320?term=ACNS0122&rank=1
Radiotherapy Alone vs. Chemotherapy Followed By Response-based Radiotherapy For Newly Diagnosed Primary CNS Germinoma
Children's Oncology Group Study ACNS0232. This randomized phase III trial is studying radiation therapy alone to see how well it works compared to chemotherapy and radiation therapy in treating patients with newly diagnosed primary CNS germ cell tumor. For further details: http://www.clinicaltrials.gov/ct/show/NCT00085098?order=1
 
Recurrent Disease
Phase I/II Study of Lapatinib (GW572016) in Pediatric Patients with Recurrent or Refractory Medulloblastoma, Malignant Glioma, or Ependymoma (PBTC 016)
This is a phaseI/II trial for patients under 21 years of age with recurrent, progressive, or refractory brain tumors. For further details: http://www.pbtc.org/public/PBTC016%20Protocol%20Abstract.pdf
Phase I Trial of CC-5013 (Lenalidomidae) in Pediatric Patients with Recurrent or Refractory Primary CNS Tumors (PBTC 018)
This is a phase I trial for children with recurrent or refractory tumors of the central nervous system. For further details: http://www.pbtc.org/public/PBTC018%20Protocol%20Abstract.pdf
A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children with Neoplastic Meningitis (PBTC 019)
This is a phase I trial for children between 3 and 21 years old with cancer that has spread to the lining of the brain and/or spinal cord (neoplastic meningitis). For further details: http://www.pbtc.org/public/PBTC-019%20Lay%20Summary.pdf
Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumors (PBTC 020)
This is a phase I trial for patients = 21 years of age with recurrent or refractory tumors of the central nervous system. For further details: http://www.pbtc.org/public/PBTC020%20Protocol%20Abstract.pdf
Phase II study of Bevacizumab plus Irinotecan (CamptosarTM) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas and Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, and Ependymomas (PBTC 022)
This is a phase II trial for children with recurrent malignant glioma and diffuse brainstem glioma. For further details: http://www.pbtc.org/public/PBTC022%20Protocol%20Abstract.pdf
Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors (PBTC 023)
This is a phase I trial for children who are less than 21 years of age and who have been diagnosed and treated previously for any type of brain tumor. For further details: http://www.pbtc.org/public/PBTC-023%20Lay%20Summary.pdf
A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors (Wyeth Protocol #3066K1-139-US)
A Phase II Study of Pmetrexed in Children with Recurrent Malignancies (COG-ADVL0525)

Pediatric Clinical Trials In Development
 
A Phase I Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors (Amgen Study 20050252)
 
For further details about clinical trials being performed at UCSF, visit http://128.218.158.34:8000/trials/index.php
 
 
UCSF UCSF Medical Center UCSF School of Medicine
Spacer
Spacer
Spacer